Helixgate

Helixgate

Uncategorized

PFAS is still in some infant formula

Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here.

Too much news yesterday, so here’s a link to a late-breaking story that the FDA has chosen Vinay Prasad’s interim successor.

Read the rest…

Read More

Published

on

Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here.

Too much news yesterday, so here’s a link to a late-breaking story that the FDA has chosen Vinay Prasad’s interim successor.

Read the rest…

Read More

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

Moderna beats revenue expectations with $389M, but litigation dogs earnings

Published

on

CEO Stéphane Bancel expressed confidence in Moderna’s first quarter, touting the revenue numbers as a sign of the company’s return to prosperity.

Continue Reading

Uncategorized

STAT+: Axsome wins FDA nod for Alzheimer’s agitation

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

The FDA named Katherine Szarama acting head of CBER as it continues to search for a permanent leader. Julia Vitarello is launching a new effort to scale bespoke medicines after her first startup faltered.

And Matt Herper reflects on the legacy of genomics pioneer J. Craig Venter, whose vision helped shape modern biotech.

Continue to STAT+ to read the full story…

Read More

Published

on

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

The FDA named Katherine Szarama acting head of CBER as it continues to search for a permanent leader. Julia Vitarello is launching a new effort to scale bespoke medicines after her first startup faltered.

And Matt Herper reflects on the legacy of genomics pioneer J. Craig Venter, whose vision helped shape modern biotech.

Continue to STAT+ to read the full story…

Read More

Continue Reading

Uncategorized

Summit slips on ivonescimab’s apparent interim miss in sign of investor frustration

Published

on

Summit Therapeutics’ stock price {$SMMT} tumbled nearly 20% after the closing bell Thursday afternoon, following an apparent statistical miss in part of a Phase 3 trial for its cancer drug ivonescimab.

In patients with a …

Continue Reading
Advertisement

Trending